

414 Rec'd PCT/PTO 0 6 OCT 2000

USPM PTO-1390 (Modified)
V 11-98)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER

TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371

1038-1094 MIS:jb

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR

09/647946

INTERNATIONAL APPLICATION NO.
PCT/CA99/00292

INTERNATIONAL FILING DATE
April 7, 1999


PRIORITY DATE CLAIMED
April 7, 1998

TITLE OF INVENTION

DNA IMMUNIZATION AGAINST CHLAMYDIA INFECTION

APPLICANT(S) FOR DO/EO/US

Robert C. Brunham



Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☐ This is an express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. ☐ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. 371 (c) (2))
 - a. ☐ is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☒ has been transmitted by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. ☐ A copy of the International Search Report (PCT/ISA/210).
8. ☐ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))
 - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ have been transmitted by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☐ have not been made and will not be made.
9. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
10. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)). - **unsigned copy**
11. ☐ A copy of the International Preliminary Examination Report (PCT/IPEA/409).
12. ☒ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).

Items 13 to 20 below concern document(s) or information included:

13. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
14. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
15. ☒ A **FIRST** preliminary amendment.
16. ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
17. ☐ A substitute specification.
18. ☐ A change of power of attorney and/or address letter.
19. ☐ Certificate of Mailing by Express Mail
20. ☐ Other items or information:

U.S. APPLIC. 09/647 946

INTERNATIONAL APPLICATION NO.
PCT/CA99/00292ATTORNEY'S DOCKET NUMBER
1038-1094 MIS:jb

21. The following fees are submitted:

BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)) :

- ☒ Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO **\$1,000.00**
- ☐ International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO **\$860.00**
- ☐ International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO **\$710.00**
- ☐ International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4) **\$690.00**
- ☐ International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4) **\$100.00**

ENTER APPROPRIATE BASIC FEE AMOUNT =**\$1,000.00**

Surcharge of **\$130.00** for furnishing the oath or declaration later than ☐ 20 ☐ 30 months from the earliest claimed priority date (37 CFR 1.492 (e)).

\$0.00

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE
Total claims	35 - 20 =	15	x \$18.00
Independent claims	5 - 3 =	2	x \$78.00

\$270.00**\$156.00**Multiple Dependent Claims (check if applicable). ☐**\$0.00****TOTAL OF ABOVE CALCULATIONS =****\$1,426.00**

Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28) (check if applicable). ☐

\$0.00**SUBTOTAL =****\$1,426.00**

Processing fee of **\$130.00** for furnishing the English translation later than ☐ 20 ☐ 30 months from the earliest claimed priority date (37 CFR 1.492 (f)).

\$0.00**TOTAL NATIONAL FEE =****\$1,426.00**

Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable). ☐

\$0.00**TOTAL FEES ENCLOSED =****\$1,426.00**

Amount to be:
refunded \$
charged \$

- ☒ A check in the amount of **\$1,396.00** to cover the above fees is enclosed.
- ☐ Please charge my Deposit Account No. _____ in the amount of _____ to cover the above fees.
A duplicate copy of this sheet is enclosed.
- ☒ The Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment to Deposit Account No. **19-2253** A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Mr. Michael I. Stewart
Sim & McBurney
6th Floor, 330 University Avenue
Toronto, Ontario
Canada, M5G 1R7.

**24223**

PATENT TRADEMARK OFFICE

SIGNATURE

Michael I. Stewart

NAME

24.973

REGISTRATION NUMBER

October 4, 2000

DATE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Our Ref: 1038-1094 MIS:jb

In re National Phase of International Application

No.: PCT/CA99/00292

International
Filing Date: April 7, 1999

Applicant: Robert C. Brunham

Title: DNA IMMUNIZATION AGAINST CHLAMYDIA INFECTION

PRELIMINARY AMENDMENT

The Commissioner of Patents
and Trademarks,
Washington, D.C. 20231,
U. S. A.

Dear Sir:

Please amend this application in the following manner:

In the Disclosure:

Before the first line of the specification, add the following:

" REFERENCE TO RELATED APPLICATIONS

This application is a national phase application under 35 U.S.C. 371 of
PCT/CA99/00292."

REMARKS

The specification has been amended on page 1 to reflect that this
application is a U.S. National Phase filing under 35 U.S.C. 371 of PCT/CA99/00292.

Respectfully submitted,



Michael I. Stewart
Reg. No. 24,973

Toronto, Ontario, Canada
(416) 595-1155
FAX No. (416) 595-1163

Date: October 4, 2000

009027 946 24960

09/647 946

TITLE OF INVENTIONDNA IMMUNIZATION AGAINST CHLAMYDIA INFECTIONFIELD OF INVENTION

5 The present invention relates to immunology and, in particular, to immunization of hosts using nucleic acid to provide protection against infection by *Chlamydia*.

BACKGROUND OF THE INVENTION

10 DNA immunization is an approach for generating protective immunity against infectious diseases (ref. 1 - throughout this application, various references are cited in parentheses to describe more fully the state of the art to which this invention pertains. Full bibliographic information for each citation is found at
15 the end of the specification, immediately preceding the claims. The disclosure of these references are hereby incorporated by reference into the present disclosure). Unlike protein or peptide based subunit vaccines, DNA immunization provides protective immunity through
20 expression of foreign proteins by host cells, thus allowing the presentation of antigen to the immune system in a manner more analogous to that which occurs during infection with viruses or intracellular pathogens (ref. 2). Although considerable interest has been
25 generated by this technique, successful immunity has been most consistently induced by DNA immunization for viral diseases (ref. 3). Results have been more variable with non-viral pathogens which may reflect differences in the nature of the pathogens, in the
30 immunizing antigens chosen, and in the routes of immunization (ref. 4). Further development of DNA vaccination will depend on elucidating the underlying immunological mechanisms and broadening its application to other infectious diseases for which existing
35 strategies of vaccine development have failed.

Chlamydia trachomatis is an obligate intracellular bacterial pathogen which usually remains localized to mucosal epithelial surfaces of the human host.

09647946-120600

Chlamydiae are dimorphic bacteria with an extracellular spore-like transmission cell termed the elementary body (EB) and an intracellular replicative cell termed the reticulate body (ref. 5). From a public health perspective, chlamydial infections are of great importance because they are significant causes of infertility, blindness and are a prevalent co-factor facilitating the transmission of human immunodeficiency virus type 1 (ref. 6). Protective immunity to *C. trachomatis* is effected through cytokines released by Th1-like CD 4 lymphocyte responses and by local antibody in mucosal secretions and is believed to be primarily directed to the major outer membrane protein (MOMP), which is quantitatively the dominant surface protein on the chlamydial bacterial cell and has a molecular mass of about 40 kDa (ref. 19).

Initial efforts in developing a chlamydial vaccine were based on parenteral immunization with the whole bacterial cell. Although this approach met with success in human trials, it was limited because protection was short-lived, partial and vaccination may exacerbate disease during subsequent infection episodes possibly due to pathological reactions to certain chlamydial antigens (ref. 8). More recent attempts at chlamydial vaccine design have been based on a subunit design using MOMP protein or peptides. These subunit vaccines have also generally failed, perhaps because the immunogens do not induce protective cellular and humoral immune responses recalled by native epitopes on the organism (ref. 9).

EP 192033 describes the provision of DNA construct for the expression, *in vitro*, of *Chlamydia trachomatis* MOMP polypeptides comprising the following operably linked elements:

a transcriptional promoter,

a DNA molecule encoding a *C. trachomatis* MOMP polypeptide comprising a MOMP polynucleotide at least 27 base pairs in length from a sequence provided in Appendix A thereto, and

5 a transcriptional terminator, wherein at least one of the transcriptional regulatory elements is not derived from *Chlamydia trachomatis*. There is no disclosure or suggestion in this prior art to effect DNA immunization with any such constructs.

10 WO 94/26900 describes the provision of hybrid picornaviruses which express chlamydial epitopes from MOMP of *Chlamydia trachomatis* and which is capable of inducing antibodies immuno-reactive with at least three different *Chlamydia* serovars. The hybrid picornavirus
15 preferably is a hybrid polio virus which is attenuated for human administration.

WO 98/02546, assigned to the assignee hereof and the disclosure of which is incorporated herein by reference, describes the DNA immunization of a host by a
20 plasmid vector comprising a nucleotide sequence encoding a major outer membrane protein (MOMP) of a strain of *Chlamydia* or encoding the N-terminal half of MOMP.

SUMMARY OF THE INVENTION

The present invention is concerned with nucleic
25 acid immunization, specifically DNA immunization, to generate in a host protective antibodies to a fragment of MOMP of a strain of *Chlamydia* that encompasses epitopic sequences. DNA immunization induces a broad spectrum of immune responses including Th1-like CD4
30 responses and mucosal immunity.

In one aspect of the invention, there is provided a non-replicating vector, comprising a nucleotide sequence encoding a region comprising at least one of the conserved domains 2, 3 and 5 of a major outer membrane
35 protein of a strain of *Chlamydia*, and a promoter sequence operatively coupled to the nucleotide sequence

for expression of the at least one conserved domain in a host.

A MOMP gene fragment that encompasses epitopic sequences may include one or more conserved domain (CD) sequences and/or one or more variable domain (VD) sequences of MOMP from a strain of *Chlamydia*. In particular, the fragment may encompass the CD2 and VD2 sequences, CD3 and VD3 sequences and CD5 sequence. Clones containing nucleotide sequences encoding such fragments are termed clones CV2, CV3 and CD5 herein. Clone CV2 encompasses nucleotides 247 to 468 of *Chlamydia trachomatis* MOMP gene, clone CV3 encompasses nucleotides 469 to 696 of *Chlamydia trachomatis* MOMP gene and clone CV5 encompasses nucleotides 931 to 1098 of *Chlamydia trachomatis* MOMP gene. The present invention employs the conserved domains 2, 3 and 5.

The strain of *Chlamydia* may be a strain of *Chlamydia* inducing chlamydial infection of the lung, including *Chlamydia trachomatis* or *Chlamydia pneumoniae*. The non-replicating vector may be plasmid pcDNA3 into which the nucleotide sequence is inserted. The immune response which is stimulated may be predominantly a cellular immune response.

In one aspect of the present invention, there is provided an immunogenic composition for *in vivo* administration to a host for the generation in the host of a protective immune response to a major outer membrane protein (MOMP) of a strain of *Chlamydia*, comprising a non-replicating vector that generates a MOMP-specific immune response, and a promoter sequence operatively coupled to the nucleotide sequence for expression of the MOMP fragment in the host; and a pharmaceutically-acceptable carrier therefor.

In a further aspect of the invention, there is provided as a method of immunizing a host against disease caused by infection with a strain of *Chlamydia*,

which comprises administering to the host an effective amount of a non-replicating vector as provided herein that generates a MOMP-specific immune response, and a promoter sequence operatively coupled to the nucleotide sequence for expression of the conserved sequence in the host.

In these aspects of the present invention, the various options and alternatives discussed above may be employed.

The non-replicating vector may be administrated to the host, including a human host, in any convenient manner, such as intramuscularly or intranasally. Intranasal administration stimulated the strongest immune response in experiments conducted herein.

The present invention also includes, in an additional aspect thereof, a method of using a nucleotide sequence encoding a MOMP fragment that generates a MOMP-specific immune response, to produce an immune response in a host, which comprises isolating the nucleotide sequence as described above, operatively linking the nucleotide sequence to at least one control sequence to produce a non-replicating vector, the control sequence directing expression of the MOMP fragment when introduced into a host to produce an immune response to the MOMP fragment, and introducing the vector into a host.

A further aspect of the present invention provides a method of producing a vaccine for protection of a host against disease caused by infection with a strain of *Chlamydia*, which comprises isolating a nucleotide sequence encoding a MOMP fragment as described above and that generates a MOMP-specific immune response, operatively linking the nucleotide sequence to at least one control sequence to produce a non-replicating vector, the control sequence directing expression of the MOMP fragment when introduced to a host to produce an

immune response to the MOMP fragment, and formulating the vector as a vaccine for *in vivo* administration to a host. The invention extends to the vaccine produced by this method.

5 Advantages of the present invention, therefore, include a method of obtaining a protective immune response to infection carried by a strain of *Chlamydia* by nucleic acid immunization of nucleic acid sequence encoding epitopic sequences of the major outer membrane
10 protein of a strain of *Chlamydia* that generate a MOMP-specific immune response.

BRIEF DESCRIPTION OF DRAWINGS

Figure 1 shows the elements and construction of plasmid pcDNA3/MOMP, 6495 bp in size.

15 Figure 2 shows schematically the nucleotide structure of the mature MOMP gene of *C. trachomatis* MoPn strain with conserved (CD) and variable (VD) domains identified as well as clones formed by cloning the identified sequences into pcDNA3, as described below in
20 the Examples.

Figure 3 shows the loss in body weight (in grams) following intranasal challenge with 5×10^3 IFU of MoPn among groups of Balb/c mice intramuscularly immunized with blank vector (pcDNA3), with pcDNA3 into which is
25 individually cloned CV1 to CD5 encoding MOMP nucleotide sequences (CV1 etc), and with pcDNA3 into which the whole MOMP encoding nucleotide sequence is cloned (pMOMP).

Figure 4 shows the results of assays to determine
30 growth of *C. trachomatis* on day 10 in lungs of mice challenged with 5×10^3 IFU of MoPn following intramuscular immunization with blank vector (pcDNA3), with pcDNA3 into which is individually cloned CV1 to CD5 encoding MOMP nucleotide sequences (pCV1 etc), and with
35 pcDNA3 into which the whole MOMP encoding nucleotide sequence is cloned (pMOMP).

09647946.1 20600

Figure 5 shows footpad swelling reactions (DTH) 48 hours after footpad injection of 2×10^5 IFU of inactivated MoPn EBs among groups of Balb/c mice intramuscularly immunized with blank pcDNA3 vector (PC), with pcDNA3 into which is individually cloned CV1 to CD5 encoding MOMP nucleotide sequences (CV1 etc), and with pcDNA3 into which the whole MOMP encoding nucleotide sequence is cloned (pM).

Figure 6 shows the proliferation responses of splenocytes at day 60 post immunization after *in vitro* stimulation with whole inactivated MoPn EBs for 96 hours among groups of Balb/c mice immunized with blank pcDNA3 vector (pc), with pcDNA3 into which is individually cloned CV1 to CD5 encoding MOMP nucleotide sequences (CV1 etc), and with pcDNA3 into which the whole MOMP encoding nucleotide sequences is cloned (pM).

Figure 7 shows the proliferation responses of splenocytes to the same constructs is in Figure 6, except that the results are expressed as a stimulation index (SI).

Figure 8 shows the interferon- γ secretion response of MoPn stimulated splenocytes collected on day 60 after immunization among groups of Balb/c mice immunized with blank pcDNA3 vector (pc), with pcDNA3 into which is individually cloned CV1 to CD5 encoding MOMP nucleotide sequences (CV1 etc), and with pcDNA3 into which the whole MoPn MOMP encoding nucleotide sequence is cloned (pM).

Figure 9 shows the IgG2a antibody titer to whole MoPn EBs using sera collected at day 60 after immunization among groups of Balb/c mice immunized with blank pcDNA3 vector (pc), with pcDNA3 into which is individually cloned CV1 to CD5 encoding MOMP nucleotide sequences (CV1 etc), and with pcDNA3 into which the whole MOMP encoding nucleotide sequences is cloned (pM).

Figure 10 shows a comparison of the amino acid sequence of MOMP sequences (SEQ ID NOS: 1 to 15) from a variety of serovars of *C. trachomatis*. Residues which are identical to serovar E MOMP are represented by dots. The four VDs (VDI to VDIV) and the conserved cysteines are boxed by solid line. The conserved position where one cysteine is located in all *C. trachomatis* and *C. pneumoniae* MOMP sequences, but where one serine is located in GPIC and Mn MOMPs, is boxed by a broken line. Numbers above boxes denote amino acid residues of serovar E MOMP only.

GENERAL DESCRIPTION OF THE INVENTION

To illustrate the present invention, plasmid DNA was constructed containing the MOMP gene fragments from the *C. trachomatis* mouse pneumonitis strain (MoPn), which is a natural murine pathogen, permitting experimentation to be effected in mice. It is known that primary infection in the model induces strong protective immunity to reinfection. For human immunization, a human pathogen strain is used, such as serovar C of *C. trachomatis*.

Any convenient plasmid vector may be used for the MOMP gene fragment, such as pcDNA3, a eukaryotic II-selectable expression vector (Invitrogen, San Diego, CA, USA), containing a cytomegalovirus promoter. The MOMP gene fragment may be inserted in the vector in any convenient manner. The gene fragments may be amplified from *Chlamydia trachomatis* genomic DNA by PCR using suitable primers and the PCR product cloned into the vector. The MOMP gene-carrying plasmid may be transferred, such as by electroporation, into *E. coli* for replication therein. Plasmids may be extracted from the *E. coli* in any convenient manner.

The plasmid containing the MOMP gene fragment may be administered in any convenient manner to the host, such as intramuscularly or intranasally, in conjunction

with a pharmaceutically-acceptable carrier. In the experimentation outlined below, it was found that intranasal administration of the plasmid DNA elicited the strongest immune response.

5 The data presented herein and described in detail below demonstrates that DNA immunization with specific *C. trachomatis* MOMP gene fragments elicits both cellular and humoral immune responses and produces significant protective immunity to lung challenge infection with *C.*
10 *trachomatis* MoPn. The results are more encouraging than those obtained using recombinant MOMP protein or synthetic peptides as the immunogen and suggest that DNA immunization is an alternative method to deliver a chlamydial subunit immunogen in order to elicit the
15 requisite protective cellular and humoral immune responses.

 The data presented herein also demonstrate the importance of selection of an antigen gene fragment for DNA immunization. As described in the aforementioned WO
20 98/02546, the antigen gene elicits immune responses that are capable of stimulating recall immunity following exposure to the natural pathogen. In particular, injection of a DNA expression vector encoding the major surface protein (pMOMP) or fragment thereof but not one
25 encoding a cytoplasmic enzyme (CTP synthetase) of *C. trachomatis*, generated significant protective immunity to subsequent chlamydial challenge. The protective immune response appeared to be predominantly mediated by cellular immunity and not by humoral immunity since
30 antibodies elicited by DNA vaccination did not bind to native EBs. In addition, MOMP DNA but not CTP synthetase DNA immunization elicited cellular immunity readily recalled by native EBs as shown by positive DTH reactions.

35 In addition, as set forth in WO 98/02546, mucosal delivery of MOMP DNA is significantly more efficient in

inducing protective immunity to *C. trachomatis* infection than intramuscular injection. This may be relevant to the nature of *C. trachomatis* infection which is essentially restricted to mucosal surfaces and the efficiency of antigen presentation (ref. 14). The rich population and rapid recruitment of dendritic cells into the respiratory epithelium of the lung may be relevant to the enhanced efficacy of intranasal DNA immunization experiments (ref. 15). The data presented in WO 98/02546 represents the demonstration of a first subunit chlamydial vaccine which engenders substantial protective immunity.

Additionally, it may be possible to amplify (and/or canalize) the protective immune response by co-administration of DNAs that express immunoregulatory cytokines in addition to the antigen gene in order to achieve complete immunity (ref. 21) The use of multiple antigen genes from chlamydiae may augment the level of protective immunity achieved by DNA vaccination.

A possible concern regarding MOMP DNA immunization according to WO 98/02546 stems from the observation that the MOMP among human *C. trachomatis* strains is highly polymorphic (ref. 16) and hence it may be difficult to generate a universal chlamydial vaccine based on this antigen gene. One way to solve this problem is to search for conserved protective epitope(s) within the MOMP molecule, as described herein. As seen in the results presented below, certain vectors containing nucleotide sequences encoding conserved and variable domains, identified in Figure 2, or conserved domains generated a protective immune response, as determined by loss of body weight, as shown in Figure 3. Figure 4 shows that the pCV3 and pCD5 immunogen evoked a protective immune response to MoPn challenge as measured by *in vivo* growth of MoPn in lung tissue day 10 post challenge and comparable to pMOMP. Figure 5 shows that

immunization with the vectors elicited variable positive DTH responses for footpad injection of MoPn Ebs.

Figures 6 and 7 show the proliferation responses of splenocytes to the vectors containing the conserved and variable domains and the whole MOMP gene. The results set forth in Figures 6 and 7 show that pCV3 and pMOMP elicit a cell mediated immune response.

Figure 8 shows interferon- γ secretion responses of the splenocytes to the vectors containing the conserved and variable domains and the whole MOMP gene. The results obtained in Figure 8 suggest that cytokine generation may not necessarily be a correlate of a protective immune response.

Another, possibly more feasible, way is to design a multivalent vaccine based on multiple MOMP genes. The latter approach is justified by the fact that the inferred amino acid sequences of MOMP among related serovars is relatively conserved (see Figure 10) and the repertoire of *C. trachomatis* gene variants appears to be finite (ref. 16).

It is clearly apparent to one skilled in the art, that the various embodiments of the present invention have many applications in the fields of vaccination, diagnosis and treatment of chlamydial infections. A further non-limiting discussion of such uses is further presented below.

1. Vaccine Preparation and Use

Immunogenic compositions, suitable to be used as vaccines, may be prepared from the MOMP gene fragments thereof and vectors as disclosed herein. The vaccine elicits an immune response in a subject which includes the production of anti-MOMP antibodies. Immunogenic compositions, including vaccines, containing the nucleic acid may be prepared as injectables, in physiologically-acceptable liquid solutions or emulsions for polynucleotide administration. The nucleic acid may be

associated with liposomes, such as lecithin liposomes or other liposomes known in the art, as a nucleic acid liposome (for example, as described in WO 93/24640) or the nucleic acid may be associated with an adjuvant, as described in more detail below. Liposomes comprising cationic lipids interact spontaneously and rapidly with polyanions, such as DNA and RNA, resulting in liposome/nucleic acid complexes that capture up to 100% of the polynucleotide. In addition, the polycationic complexes fuse with cell membranes, resulting in an intracellular delivery of polynucleotide that bypasses the degradative enzymes of the lysosomal compartment. WO 94/27435 describes compositions for genetic immunization comprising cationic lipids and polynucleotides. Agents which assist in the cellular uptake of nucleic acid, such as calcium ions, viral proteins and other transfection facilitating agents, may advantageously be used.

Polynucleotide immunogenic preparations may also be formulated as microcapsules, including biodegradable time-release particles. Thus, U.S. Patent 5,151,264 describes a particulate carrier of a phospholipid/glycolipid/polysaccharide nature that has been termed Bio Vecteurs Supra Moléculaires (BVSM). The particulate carriers are intended to transport a variety of molecules having biological activity in one of the layers thereof.

U.S. Patent 5,075,109 describes encapsulation of the antigens trinitrophenylated keyhole limpet hemocyanin and staphylococcal enterotoxin B in 50:50 poly (DL-lactide-co-glycolide). Other polymers for encapsulation are suggested, such as poly(glycolide), poly(DL-lactide-co-glycolide), copolyoxalates, polycaprolactone, poly(lactide-co-caprolactone), poly(esteramides), polyorthoesters and poly(8-hydroxybutyric acid), and polyanhydrides.

WO 91/06282 describes a delivery vehicle comprising a plurality of bioadhesive microspheres and antigens. The microspheres being of starch, gelatin, dextran, collagen or albumin. This delivery vehicle is particularly intended for the uptake of vaccine across the nasal mucosa. The delivery vehicle may additionally contain an absorption enhancer.

The MOMP gene fragment containing non-replicating vectors may be mixed with pharmaceutically acceptable excipients which are compatible therewith. Such excipients may include, water, saline, dextrose, glycerol, ethanol, and combinations thereof. The immunogenic compositions and vaccines may further contain auxiliary substances, such as wetting or emulsifying agents, pH buffering agents, or adjuvants to enhance the effectiveness thereof. Immunogenic compositions and vaccines may be administered parenterally, by injection subcutaneously, intravenously, intradermally or intramuscularly, possibly following pretreatment of the injection site with a local anesthetic. Alternatively, the immunogenic compositions formed according to the present invention, may be formulated and delivered in a manner to evoke an immune response at mucosal surfaces. Thus, the immunogenic composition may be administered to mucosal surfaces by, for example, the nasal or oral (intragastric) routes. Alternatively, other modes of administration including suppositories and oral formulations may be desirable. For suppositories, binders and carriers may include, for example, polyalkylene glycols or triglycerides. Oral formulations may include normally employed excipients, such as, for example, pharmaceutical grades of saccharine, cellulose and magnesium carbonate.

The immunogenic preparations and vaccines are administered in a manner compatible with the dosage

formulation, and in such amount as will be therapeutically effective, protective and immunogenic. The quantity to be administered depends on the subject to be treated, including, for example, the capacity of the individual's immune system to synthesize the MOMP and antibodies thereto, and if needed, to produce a cell-mediated immune response. Precise amounts of active ingredient required to be administered depend on the judgement of the practitioner. However, suitable dosage ranges are readily determinable by one skilled in the art and may be of the order of about 1 μ g to about 1 mg of the MOMP gene-containing vectors. Suitable regimes for initial administration and booster doses are also variable, but may include an initial administration followed by subsequent administrations. The dosage may also depend on the route of administration and will vary according to the size of the host. A vaccine which protects against only one pathogen is a monovalent vaccine. Vaccines which contain antigenic material of several pathogens are combined vaccines and also belong to the present invention. Such combined vaccines contain, for example, material from various pathogens or from various strains of the same pathogen, or from combinations of various pathogens.

Immunogenicity can be significantly improved if the vectors are co-administered with adjuvants, commonly used as 0.05 to 0.1 percent solution in phosphate-buffered saline. Adjuvants enhance the immunogenicity of an antigen but are not necessarily immunogenic themselves. Adjuvants may act by retaining the antigen locally near the site of administration to produce a depot effect facilitating a slow, sustained release of antigen to cells of the immune system. Adjuvants can also attract cells of the immune system to an antigen depot and stimulate such cells to elicit immune responses.

Immunostimulatory agents or adjuvants have been used for many years to improve the host immune responses to, for example, vaccines. Thus, adjuvants have been identified that enhance the immune response to antigens. 5 Some of these adjuvants are toxic, however, and can cause undesirable side-effects, making them unsuitable for use in humans and many animals. Indeed, only aluminum hydroxide and aluminum phosphate (collectively commonly referred to as alum) are routinely used as 10 adjuvants in human and veterinary vaccines.

A wide range of extrinsic adjuvants and other immunomodulating material can provoke potent immune responses to antigens. These include saponins complexed to membrane protein antigens to produce immune 15 stimulating complexes (ISCOMS), pluronic polymers with mineral oil, killed mycobacteria in mineral oil, Freund's complete adjuvant, bacterial products, such as muramyl dipeptide (MDP) and lipopolysaccharide (LPS), as well as Quil A derivatives and components thereof, QS 20 21, calcium phosphate, calcium hydroxide, zinc hydroxide, an octodecyl ester of an amino acid, ISCOPREP, DC-chol, DDBA and polyphosphazene. Advantageous combinations of adjuvants are described in copending United States Patent Applications Nos.: 25 08/261,194 filed June 16, 1994 and 08/483,856 filed June 7, 1995, assigned to the assignee hereof and the disclosures of which are incorporated herein by reference thereto (WO 95/34308).

In particular embodiments of the present invention, 30 the non-replicating vector comprising a first nucleotide sequence encoding a MOMP gene fragment of *Chlamydia* may be delivered in conjunction with a targeting molecule to target the vector to selected cells including cells of the immune system.

35 The non-replicating vector may be delivered to the host by a variety of procedures, for example, Tang et

00647946 "120600

al. (ref. 17) disclosed that introduction of gold microprojectiles coated with DNA encoding bovine growth hormone (BGH) into the skin of mice resulted in production of anti-BGH antibodies in the mice, while
5 Furth et al. (ref. 18) showed that a jet injector could be used to transfect skin, muscle, fat and mammary tissues of living animals.

2. Immunoassays

The MOMP gene fragments and vectors of the present
10 invention also are useful as immunogens for the generation of anti-MOMP antibodies for use in immunoassays, including enzyme-linked immunosorbent assays (ELISA), RIAs and other non-enzyme linked antibody binding assays or procedures known in the art.
15 In ELISA assays, the non-replicating vector first is administered to a host to generate antibodies specific to the MOMP. These MOMP specific antibodies are immobilized onto a selected surface, for example, a surface capable of binding the antibodies, such as the wells of a polystyrene microtiter plate. After washing
20 to remove incompletely adsorbed antibodies, a nonspecific protein, such as a solution of bovine serum albumin (BSA) that is known to be antigenically neutral with regard to the test sample, may be bound to the selected surface. This allows for blocking of
25 nonspecific adsorption sites on the immobilizing surface and thus reduces the background caused by nonspecific bindings of antisera onto the surface.

The immobilizing surface is then contacted with a
30 sample, such as clinical or biological materials, to be tested in a manner conducive to immune complex (antigen/antibody) formation. This procedure may include diluting the sample with diluents, such as solutions of BSA, bovine gamma globulin (BGG) and/or
35 phosphate buffered saline (PBS)/Tween. The sample is then allowed to incubate for from about 2 to 4 hours, at

temperatures such as of the order of about 20° to 37°C. Following incubation, the sample-contacted surface is washed to remove non-immunocomplexed material. The washing procedure may include washing with a solution, such as PBS/Tween or a borate buffer. Following formation of specific immunocomplexes between the test sample and the bound MOMP specific antibodies, and subsequent washing, the occurrence, and even amount, of immunocomplex formation may be determined.

EXAMPLES

The above disclosure generally describes the present invention. A more complete understanding can be obtained by reference to the following specific Examples. These Examples are described solely for purposes of illustration and are not intended to limit the scope of the invention. Changes in form and substitution of equivalents are contemplated as circumstances may suggest or render expedient. Although specific terms have been employed herein, such terms are intended in a descriptive sense and not for purposes of limitation.

Example 1:

This Example illustrates the preparation of a plasmid vector containing the MOMP gene, as also described in WO 98/02546.

pMOMP expression vector was made as follows. The MOMP gene was amplified from *Chlamydia trachomatis* mouse pneumonitis (MoPn) strain genomic DNA by polymerase chain reaction (PCR) with a 5' primer (GGGGATCCGCCACCATGCTGCCTGTGGGGAATCCT) (SEQ ID NO: 16) which includes a BamH1 site, a ribosomal binding site, an initiation codon and the N-terminal sequence of the mature MOMP of MoPn and a 3' primer (GGGGCTCGAGCTATTAACGGAAGTGAAGC) (SEQ ID NO: 17) which includes the C-terminal sequence of the MoPn MOMP, a XhoI site and a stop codon. The DNA sequence of the MOMP

leader peptide gene sequence was excluded. After digestion with BamH1 and Xho1, the PCR product was cloned into the pcDNA3 eukaryotic II-selectable expression vector (Invitrogen, San Diego) with transcription under control of the human cytomegalovirus major intermediate early enhancer region (CMV promoter). The MOMP gene-encoding plasmid was transferred by electroporation into *E. coli* DH5 α F which was grown in LB broth containing 100 μ g/ml of ampicillin. The plasmids was extracted by WizardTM Plus Maxiprep DNA purification system (Promega, Madison). The sequence of the recombinant MOMP gene was verified by PCR direct sequence analysis, as described (ref. 20). Purified plasmid DNA was dissolved in saline at a concentration of 1 mg/ml. The DNA concentration was determined by a DU-62 spectrophotometer (Beckman, Fullerton, CA) at 260 nm and the size of the plasmid was compared with DNA standards in ethidium bromide-stained agarose gel.

The MOMP gene containing so obtained plasmid, pcDNA3/MOMP, and its constitutive elements are shown in Figure 1. A similar plasmid (pM(C)) was constructed from the MOMP gene serovar C of *C. trachomatis*.

For experimental design, groups of 4 to 5 week old female Balb/c mice (5 to 13 per group) were immunized intramuscularly (IM) or intranasally (IN) with plasmid DNA containing the coding sequence of the MoPn MOMP gene (1095 bp), prepared as described in Example 1, or with the coding sequence of the *C. trachomatis* serovar L₂ CTP synthetase gene (1619 bp (refs. 10, 12), prepared by a procedure analogous described in Example 1. CTP synthetase is a conserved chlamydial cytoplasmic enzyme catalyzing the final step in pyrimidine biosynthesis and is not known to induce protective immunity. Negative control animals were injected with saline or with the plasmid vector lacking an inserted chlamydial gene.

Example 2:

This Example illustrates DNA immunization of mice and the results of DTH testing.

5 A model of murine pneumonia induced by the *C. trachomatis* mouse pneumonitis strain (MoPn) was used (ref. 11). Unlike most strains of *C. trachomatis* which are restricted to producing infection and disease in humans, MoPn is a natural murine pathogen. It has previously been demonstrated that primary infection in
10 this model induces strong protective immunity to reinfection. In addition, clearance of infection is related to CD4 Th1 lymphocyte responses and is dependent on MHC class II antigen presentation (ref. 11).

For IM immunization, both guardiceps were injected
15 with 100 µg DNA in 100 µl of saline per injection site on three occasions at 0, 3 and 6 weeks. For IN immunization, anaesthetized mice aspirated 25 µl of saline containing 50 µg DNA on three occasions at 0, 3 and 6 weeks. As a positive control, a separate group of
20 mice received 5×10^6 inclusion forming units (IFUs) of MoPn EBs administered intraperitoneally in incomplete Freund's adjuvant according to the above schedule. At week 8, all groups of mice had sera collected for measuring antibodies and were tested for delayed-type
25 hypersensitivity (DTH) to MoPn Ebs by footpad injection (ref. 13).

A positive 48 and 72 hour DTH reaction was detected among mice immunized with MOMP DNA or with MoPn Ebs but not among mice immunized with the blank vector (see
30 Figure 1 of WO 98/02546). The DTH reaction elicited with MOMP DNA delivered intranasally was comparable to that observed among mice immunized with EBs. No DTH reaction was detected among the groups of mice vaccinated with CTP synthetase DNA (see Table 1 below). Thus, injection
35 of MOMP DNA generated a DTH reaction that was capable of

recall by naturally processed peptides from *C. trachomatis* EBs while injection of CTP synthetase DNA failed to do so.

Example 3:

5 This Example illustrates DNA immunization of mice and the generation of antibodies.

Injection of CTP synthetase DNA as described in Example 2 resulted in the production of serum antibodies to recombinant CTP synthetase (Table 1) (ref. 14).
10 Antigen-specific serum Abs were measured by ELISA. Flat-bottom 96-well plates (Corning 25805, Corning Science Products, Corning, NY) were coated with either recombinant chlamydial CTP-synthetase (1 µg/ml) or purified MoPn EBs (6×10^4 IFU/well) overnight at 4°C.
15 The Plates were rinsed with distilled water and blocked with 4% BSA PBS-Tween and 1% low fat skim milk for 2 hours at room temperature. Dilutions of sera samples were performed in 96-well round bottom plates immediately prior to application on the antigen coated
20 plates. The plates were incubated overnight at 4°C and washed ten times. Biotinylated goat anti-mouse IgG1 or goat anti-mouse IgG2a (Southern Biotechnology Associates, Inc. Birmingham, AL) were next applied for 1 hour at 37°C. After washing, streptoavidin-alkaline
25 phosphatase conjugate (Jackson ImmunoResearch Laboratories, Inc. Mississauga, Ontario, Canada) were added and incubated at 37°C for 30 min. Following another wash step, phosphatase substrate in phosphatase buffer (pH 9.8) was added and allowed to develop for 1
30 hour. The plates were read at 405 nm on a BIORAD 3550 microplate reader.

IgG2a antibody titers were approximately 10-fold higher than IgG1 antibody titers suggesting that DNA immunization elicited a more dominant T_H1 -like response.
35 Injection of MOMP DNA as described in Example 2 resulted

in the production of serum antibodies to MOMP (Table 2) as detected in an immunoblot assay (Figure 2 of WO 98/02546). However, neither CTP synthetase DNA nor MOMP DNA immunized mice produced antibodies that bound to native *C. trachomatis* EBs (Table 1), suggesting that the antibody responses may not to be the dominantly protective mechanism.

Example 4:

This Example illustrates DNA immunization of mice to achieve protection.

To investigate whether a cell-mediated immune response elicited by MOMP DNA was functionally significant, *in vivo* protective efficacy was evaluated in mice challenged intranasally with 1×10^3 IFU of *C. trachomatis* MoPn. To provide a measure of Chlamydia-induced morbidity, the loss in body weight was measured over 10 days following challenge with *C. trachomatis*. Mice injected with the unmodified vector were used as negative controls and mice immunized with EBs were used as positive controls. Mice immunized with MOMP DNA intranasally maintained a body weight comparable to that observed among EB immunized mice. Mice intramuscularly immunized with MOMP DNA lost body mass but did so at a rate less than the negative control group.

A more direct measure of the effectiveness of DNA vaccination is the ability of mice immunized with MOMP DNA to limit the *in vivo* growth of Chlamydia following a sublethal lung infection. Day 10 post-challenge is the time of peak growth (ref. 13) and was chosen for comparison of lung titers among the various groups of mice. Mice intranasally immunized with MOMP DNA had chlamydial lung titers that were over 1000-fold lower (\log_{10} IFU 1.3 ± 0.3 ; mean \pm SEM) than those of control mice immunized with the blank vector (\log_{10} IFU 5.0 ± 0.3 ; $p < 0.01$). Mice intramuscularly immunized with MOMP DNA had chlamydial lung titers that were more than 10-fold

lower than the unmodified vector group ($p = 0.01$). Mice intranasally immunized with MOMP DNA had significantly lower chlamydial lung titers than mice immunized with MOMP DNA intramuscularly (\log_{10} IFU 1.3 ± 0.8 versus \log_{10} IFU 0.66 ± 0.3 respectively; $p = 0.38$). The substantial difference (2.4 logs) in chlamydial lung titers observed between the intranasally and intramuscularly MOMP DNA immunized mice suggests that mucosal immunization is more efficient at inducing immune responses to accelerate chlamydial clearance in the lung. The lack of protective effect with the unmodified vector control confirms that DNA per se was not responsible for the immune response. Moreover, the absence of protective immunity following immunization with CTP synthetase DNA confirms that the immunity was specific to the MOMP DNA (see Table 1).

Example 5:

This Example describes the construction of plasmids containing fragments of MOMP DNA.

A series of vectors was generated following the procedure outlined in Example 1 containing fragments of the nucleotide sequence of the MoPn MOMP gene by PCR cloning and subsequent cloning into the vector pcDNA3 to generate plasmids pCV1, pCV2, pCV3, pCV4 and pCD5, respectively, containing the respective fragments of the MoPn MOMP gene shown in Figure 2.

Example 5:

This Example illustrates immunization of mice with pCV1, pCV2, pCV3, pCV4 and pCD5.

Balb/c mice were immunized in the quadriceps three times at a three week intervals with 100 μ g of pCV1, pCV2, pCV3, pCV4 and pCD5 DNA, following the procedure described in Example 2.

Fifteen days after the last immunization and 60 days after the first injection, mice were bled for

measurement of serum antibodies of MoPn EBs in an EIA assay and were injected in the footpad with 25 μ l (5×10^4 inclusion forming units) of heat killed EBs for measurement of DTH which was measured at 72 hours (ref. 13). Mice were intranasally challenged with 1000 infectious units of MoPn and their body weight measured daily for the subsequent 10 days. At that time, mice were sacrificed and quantitative cultures of MoPn in the lung determined (ref. 13).

Figure 3 shows that pCV2, pCV3 and pCD5 immunization evoked a protective immune response to MoPn challenge as measured by loss in body weight post infection comparable to that in mice protected against disease. Figure 4 shows that pCV3 and pCD5 immunization evoked a protective immune response to MoPn challenge as measured by *in vivo* growth of MoPn in lung tissue, comparable to pMOMP.

However, the specific domains eliciting these immune responses do not include those predicted in the art to contain T-cell epitopes. In this regard, several groups have attempted to define MOMP T-cell epitopes (refs. 22 to 26). All of those studies used overlapping synthetic peptides to various regions of the MOMP protein to prime mice. None of the predicted epitopes fall within regions that have been found to be protective.

Figure 5 shows that immunization with pCV1, pCV2, pCV3, pCV4 and pCD5 elicited variable positive DTH responses to footpad injection of MoPn EBs. pCV3 and pCD5 elicited greater responses, comparable to pMOMP. Immunization with the unmodified vector elicited neither serum antibodies nor a DTH response.

Figure 9 shows IgG_{2a} antibody titers in sera collected from the mice 60 days post immunization by the vectors containing the conserved and variable domains and full length MOMP gene. Only in the case of

immunization by pCV3 and pCD5, was an IgG_{2a} immune response generated, indicating that a Th1-like response was elicited by these vectors.

As may be seen in this Example, the vectors containing specific segments of the MOMP gene were able to protect against disease, based on body weight loss, namely pCV2 and pCD5. In addition, vectors pCV3 and pCD5 were able to protect against infection, based on lung titres.

Example 6

This Example illustrates the proliferation response of splenocytes to the vectors pMOMP, pCV1, pCV2, pCV3, pCV4 and pCD5.

Mice were sacrificed two weeks after the fourth immunization following the protocol of Example 2. The spleens were removed and single-cell suspensions were prepared. 200 µl of the cell suspension (5×10^5 well) in RPMI-1640 medium containing 10% heat-inactivated fetal calf serum (FCS), 1% L-glutamine and 5×10^{-5} M 2-mercaptoethanol (2ME, Kodak, Rochester, NY) were incubated with 1×10^5 IFU/ml of MoPn in 96 well flat bottom plates in triplicate 37°C in 5% CO₂ for 96 hours. Negative control wells contained spleen cells without antigen and positive control wells contained spleen cells with 0.25 µg/ml of concanavalin A. 0.25 µCi/well of tritiated (³H) thymidine (2 Ci/mmol, 74 Gbq/mmol, imCi/ml, ICN, Irvine, CA) was added after 3 days of culture and 16h before harvest. The cells were harvested with a PHD cell harvester (Cambridge Technology Inc., Watertown, MA, USA) and counted in 2ml of scintillation solution (Universal, ICN, Costa Mesa) in a Beckman LS5000 counter (Beckman Instrument, UK).

As may be seen in the results presented into Figures 6 and 7, pCV3 and pMOMP elicited a cell-mediated immune response.

Example 7

This Example illustrates the interferon- γ secretion responses of splenocytes to the vectors pMOMP, pCV1, pCV2, pCV3, pCV4 and pCD5.

5 A cytokine-specific ELISPOT assay was used for the quantification of murine IFN γ and IL-10 secreting cells in the murine spleen. For all assays 96-well nitrocellulose-based microtiters (Milititer Multiscreen HA plates, Millipore Corp, Molshem, France) were coated
10 overnight at 4°C with 100 μ l of the anti-cytokine mAb diluted in PBS at a concentration of 5 μ g/ml. After removing the coating solution from the plates, wells were blocked for at least 1 hour with RPMI-1640 media containing 40% fetal calf serum at 37°C, in CO $_2$. After
15 rinsing the plates with PBS-T once, the testing cells were added into the wells.

For induction of antigen specific IFN γ secreting cells in immunized mice, single cells were adjusted to 5 x 10 6 cells/ml and cultured with 2 x 10 5 IFU/ml of UV-
20 killed EB of MoPn in 24 well plates for 72 hours. After washing with RPMI 1640, cells were added onto the 96-well plates for 72 hours. After washing with RPMI 1640, cells were added onto the 96-well nitrocellulose-based microtiter plates which had been previously coated with
25 anti-cytokine antibodies. The cells were added to individual wells (2 x 10 5 or 1 x 10 5 /100- μ l/well) and incubated for 24 hours at 37°C in a CO $_2$ incubator. Wells were rinsed extensively with PBS-T containing 1% BSA. Following rinsing with PBS-T three times (removing the
30 supporting manifold and washing the back of the plate thoroughly with PBS-T), alkaline phosphatase conjugated streptavidin in PBS containing 1% BSA at 1:2000 at a concentration of 0.5 μ g/ml was added and incubated at 37°C in CO $_2$ for 45 min. After rinsing thoroughly, 100

5

10

SUMMARY OF DISCLOSURE

15

20

Table 1

Serum antibody titers and delayed-type hypersensitivity (DTH) responses and *in vivo* growth of *Chlamydia trachomatis* following pCTP synthetase or MoPn EB immunization. Results are presented as means \pm SEM.

	Anti-MoPn EB antibodies (\log_{10})		anti-rCTP synthetase antibodies (\log_{10})		Anti-EB DTH (mm \times 10 ²)	\log_{10} IFU/lung d10 post challenge
	IgG1	IgG2a	IgG1	IgG2a		
Saline (n = 9)	<2	<2	<2	<2	4.5 \pm 1.5	4.9 \pm 2.4
pCTP synthetase (n = 11)	<2	<2	3.8 \pm .3	4.7 \pm .1	1.4 \pm 1.5	4.7 \pm .13
EB (n = 4)	5.0 \pm .3	4.8 \pm .3	3.6 \pm .8	2.9 \pm 0	15.2 \pm 2.0	0

Table 2

Serum antibody Elisa titers to *Chlamydia trachomatis* mouse pneumonitis recombinant MOMP and EBs were measured 60 days after the initial immunization among mice immunized with blank vector alone (pcDNA3), vector containing the MOMP gene (pMOMP) and vector containing the CTP synthetase gene (pCTP). Non-immunized mice were also tested.

Immunogen	rMOMP		EB	
	IgG2a	IgG1	IgG2a	IgG1
pcDNA3	<2.6*	<2.6	<2.6	<2.6
pMOMP	3.77 ± 0.1	2.90 ± 0.14	3.35 ± 0.11	<2.6
pCTP	ND	ND	<2.6	<2.6
Preimmunization	<2.6	<2.6	<2.6	<2.6

* log₁₀ mean ± SE IgG isotype specific antibody titer

ND = not done

REFERENCES

1. M.A. Liu, M.R. Hilleman, R. Kurth, Ann. N.Y. Acad. Sci. 772 (1995).
2. D.M. Pardoll and A.M. Beckerieg, Immunity 3, 165 (1995); W.M. McDonnell and F.K. Askari, N. Engl. J. Med. 334, 42 (1996).
3. J.B. Ulmer et al., Science 259, 1745 (1993); B. Wang et al., Proc. Natl. Acad. Sci. USA 90, 4156 (1993); G.J.M. Cox, T.J. Zamb, L.A. Babiuk, J. Virol. 67, 5664 (1993); E. Raz et al., Proc. Natl. Acad. Sci. USA, 91,9519 (1994); Z.Q. Xiang et al., Virology 199, 132 (1994); J.J. Donnelly et al., J. Infect. Dis. 713, 314 (1996); D.L. Montgomery et al., DNA. Cell. Biol. 12, 777 (1993); J.J. Donnelly et al., Nature Medicine 1, 583 (1995); G.H. Rhodes et al., Dev. Biol. Stand. 82, 229 (1994); H.L. Davis, M.L. Michel, R.G. Whalen, Human Molecular Genetics 2, 1847 (1993); J.B. Ulmer et al., Vaccine 12, 1541 (1994); Z. Xiang and H.C.J. Ertl. Immunity 2, 129 (1995); E.F. Fynan et al, Proc. Natl. Acad. Sci. USA 90, 11478 (1993); E. Manickan, R.J.D. Rouse, Z. Yu, J. Immunol. 155, 259 (1995).
4. M. Sedegah, R. Hedstrom, P. Hobart, S.L. Hoffman, Proc. Natl. Acad. Sci. USA 91, 9866 (1994); M.A. Barry, W.C. Lai, S.A. Johnston, Nature 377, 632 (1995); D. Xu and F.Y. Liew, Vaccine 12, 1534 (1994); D.B. Lowrie, R.E. Tascon, M.J. Colston, Vaccine 12, 1537 (1994).
5. J.W. Moulder, Microbiol. Rev. 55, 143 (1991).
6. J. Schachter, Curr. Top. Microbiol. Immunol. 138, 109 (1988); S.D. Hillis and J.N. Wasserheit, N. Engl. J. Med. 334, 1399 (1996).
7. R.C. Brunham and R.W. Peeling, Infectious Agents and Disease 3, 218 (1994); R.P. Morrison, D.S. Manning, H.D. Caldwell, in Advances in Host Defence Mechanisms, T.C. Quin, Ed. (Raven Press, New York, 1992), pp 57-84.
8. J.T. Grayston and S.-P. Wang, Sex. Trans. Dis. 5, 73 (1978); J.T. Grayston and S.-P. Wang, J. Infect. Dis. 132, 87 (1975).
9. H.R. Taylor, J. Whittum-Hudson, J. Schachter, Invest. Ophthalmol. Vis. Sci. 29, 1847 (1988); B.E. Batteiger, R.G. Rank, P.M. Bavoil, J. Gen. Microbiol. 139, 2965 (1993); M. Campos et al., Invest. Ophthalmol. Vis. Sci. 36, 1477 (1995); H. Su, M. Parnell, H.D. Caldwell, Vaccine 13, 1023 (1995); T.-W. Tan, A.J. Herring, I.E. Anderson, Infect. Immun.

009021 94624960

- 58, 3101 (1990); M. Tuffrey, F. Alexander, W. Conlan, J. Gen. Microbiol. 138, 1707 (1992).
10. Y.-X. Zhang, J.G. Fox, Y. Ho, Mol. Biol. Evol. 10, 1327 (1993).
 11. R.P. Morrison, K. Feilzer, D.B. Tumas, Infect. Immun. 63, 4661 (1995); H. Su and H.D. Caldwell, Infect. Immun. 63, 3302 (1995); J.U. Igietseme et al., Reg. Immunol. 5, 317 (1993); J.U. Igietseme and R.G. Rank, Infect. Immun. 59, 1346 (1991); D.M. Williams, J. Schachter, J.J. Coalson, J. Infect. Dis. 149, 630 (1984).
 12. G. Tipples and G. McClarty, J. Biol. Chem. 270, 7908 (1995).
 13. X. Yang, K.T. HayGlass, R.C. Brunham, J. Immunol., 156, 4338 (1996).
 14. H. Su and H.D. Caldwell, Infect. Immun. 63, 946 (1995).
 15. A.S. McWilliam, D. Nelson, J.A. Thomas, J. Exp. Med. 179, 1331 (1994); M.R. Neutra, E. Pringault, J.-P. Kraehenbuhl, Annu. Rev. Immunol. 14, 275 (1996); J.M. Austyn, J. Exp. Med. 183, 1287 (1996).
 16. R. Brunham et al., J. Clin. Invest. 94, 458 (1994); R.C. Brunham et al., J. Infect. Dis. 173, 950 (1996).
 17. Tang et al., Nature 1992, 356: 152-154.
 18. Furth et al., Vaccine 1994, 12: 1503-1509.
 19. Morrison RP, Manning DS, Caldwell HD. Immunology of *Chlamydia trachomatis* infections: Immunoprotective and immunopathogenetic responses. In: Quin TC. Advances in host defence mechanisms. Sexually transmitted diseases. Vol. 8. New York: Raven Press, 1992: 52-84.
 20. Brunham R., Yang C., Maclean I., Kimani J., Maitha G., Plummer F., *Chlamydia trachomatis* from individuals in a sexually transmitted disease core group exhibit frequent sequence variation in the major outer membrane protein (omp1) gene. J. Clin. Invest. 1994; 94:458-63.
 21. Xiang Z. Ertl HCJ. Manipulation of the immune response to a plasmid-encoded viral antigen by coinoculation with plasmids expressing cytokines. Immunity 1995: 2:129-35.

009951745 WO 99/51745

22. Holland M.J. et al, Synthetic peptides based on Chlamydia trachomatis antigens identify cytotoxic T lymphocyte responses in subjects from a trachoma-endemic population. Clin. Exp. Immunol. 1997 Jan; 107(1):44-49.
23. Su H. et al., Identification and characterization of T helper cell epitopes of the major outer membrane protein of Chlamydia trachomatis. J. Exp. Med. 1990 Jul 1; 172(1):203-212.
24. Su H. et al, Immunogenicity of a chimeric peptide corresponding to T helper and B cell epitopes of the Chlamydia trachomatis major outer membrane protein. J. Exp. Med. 1992, Jan 1; 175(1): 227-235.
25. Allen J.E. et al., A single peptide from the major outer membrane protein of Chlamydia trachomatis elicits T cell help for the production of antibodies to protective determinants. J. Immunol. 1991, Jul. 15;147(2):674-679.
26. Knight S.C. et al, A peptide of Chlamydia trachomatis shown to be a primary T-cell epitope in vitro induces cell-mediated immunity in vivo. PMID: 1712817, UI:91302820.

009027 0464960

NOT 34 ADPT

32

CLAIMS

What I claim is:

1. A non-replicating vector, comprising:
 - a nucleotide sequence encoding a region which is at least one of the conserved domains 2, 3 and 5 of a major outer membrane protein of a strain of *Chlamydia*, and
 - a promoter sequence operatively coupled to said nucleotide sequence for expression of said at least one conserved domain in a host.
2. The vector of claim 1 wherein said nucleotide sequence encoding the conserved domain 2 and/or 3 further includes a nucleotide sequence encoding a variable domain of the major outer membrane protein immediately downstream of the conserved domain.
3. The vector of claim 1 wherein said nucleotide sequence encodes the conserved domain 5 of the outer membrane protein.
4. The vector of claim 1 wherein said promoter sequence is the cytomegalovirus promoter.
5. The vector of claim 1 wherein said non-replicating vector comprises plasmid pCDNA3 containing said promoter sequence and into wherein said nucleotide sequence is inserted in operative position to said promoter sequence.
6. The vector of claim 5 wherein said strain of *Chlamydia* is a strain producing chlamydial infectious of the lung.
7. The vector of claim 5 wherein said strain of *Chlamydia* is a strain of *Chlamydia trachomatis*.
8. An immunogenic composition for in vivo administration to a host for the generation in the host of a protective immune response to a fragment of a major outer membrane protein (MOMP) of a strain of *Chlamydia*, comprising a non-replicating vector comprising:
 - a nucleotide sequence encoding a region which is at least one of the conserved domains 2, 3 and 5 of a major

009900292-120600

outer membrane protein of a strain of *Chlamydia* and that generates a MOMP-specific immune response, and

a promoter sequence operatively coupled to said nucleotide sequence for expression of said MOMP or MOMP fragment in the host; and

a pharmaceutically-acceptable carrier therefor.

9. The immunogenic composition of claim 8 wherein said nucleotide sequence encoding the conserved domain 2 and/or 3 further includes a nucleotide sequence encoding a variable domain of the major outer membrane protein immediately downstream of said conserved domain.

10. The immunogenic composition of claim 8 wherein said nucleotide sequence encodes the conserved domain 5 of a major outer membrane protein of a strain of *Chlamydia*.

11. The immunogenic composition of claim 8 wherein said promoter sequence is the cytomegalovirus promoter.

12. The immunogenic composition of claim 1 wherein said strain of *Chlamydia* is a strain producing chlamydial infections of the lung.

13. The immunogenic of claim 8 wherein said strain of *Chlamydia* is a strain of *Chlamydia trachomatis*.

14. The immunogenic composition of claim 13 wherein said non-replicating vector comprises plasmid pcDNA3 containing said promoter sequence and into which said nucleotide sequence is inserted in operative relation to said promoter sequence.

15. The composition of claim 8 wherein said immune response is predominantly a cellular immune response.

16. A method of immunizing a host against disease caused by infection with a strain of *Chlamydia*, which comprises administering to said host an effective amount of a non-replicating vector comprising:

a nucleotide sequence encoding a region which is at least one of the conserved domains 2, 3, and 5 of a major

outer membrane protein of a strain of *Chlamydia* and that generates a MOMP-specific immune response, and

a promoter sequence operatively coupled to said nucleotide sequence for expression of said MOMP in the host.

17. The method of claim 16 wherein said promoter sequence is the cytomegalovirus promoter.

18. The method of claim 16 wherein said strain of *Chlamydia* is a strain producing chlamydial infections of the lung.

19. The method of claim 16 wherein said strain of *Chlamydia* is a strain of *Chlamydia trachomatis*.

20. The method of claim 16 wherein said non-replicating vector comprises plasmid pcDNA3 containing said promoter into which said nucleotide sequence is inserted in operative relation to said promoter sequence.

21. The method of claim 16 wherein said immune response is predominantly a cellular immune response.

22. The method of claim 16 wherein said non-replicating vector is administered intranasally.

23. The method of claim 16 wherein said host is a human host.

24. A method of using a nucleotide sequence encoding a fragment of a major outer membrane protein (MOMP) of a strain of *Chlamydia* that generates a MOMP-specific immune response, to produce an immune response in a host, which comprises:

isolating said nucleotide sequence encoding a region which is at least one of the conserved domains 2, 3 and 5 of a major outer membrane protein of a strain of *Chlamydia*,

operatively linking said nucleotide sequence to at least one control sequence to produce a non-replicating vector, said control sequence directing expression of said

36

operatively linking said nucleotide sequence to at least one control sequence to produce a non-replicating vector, the control sequence directing expression of said MOMP fragment when introduced to a host to produce an immune response to said MOMP fragment, and

formulating said vector as a vaccine for in vivo administration to a host.

35. A vaccine produced by the method of claim 34.

009900292 94624950




FIG.1




FIG.2




FIG.3




FIG.4




FIG.5




FIG.6




FIG.7




FIG.8




FIG.9

FIG.10A

	1	26	
E	MKKLLKSVLVFAAL-SSASSLQALPVGNPAEPSIMIDGILWEGFGDP	C D	
B-		
L1-		
DA-		
L2-		
F-		
L3-		
A-		
C-		
H-		
MoPnA.V.-G...H.....		
SFPDA.V.-G...H.....		
GPICA.L...T-G.L.....L...TM...AS...		
MnA.L...TT-G.L.....L...TM...AS...		
HuPnA.LS..FAG.VG.....SD...L...TI...AA...		
	29	23	59
	P C T T W C	DAISRMGYGDFVFDRLKIDVNK	EFQ-MGDKPTSTIGVATAPT
-A...T....V..S.
Q.....	...-A...A...A..S.
E.....	..H-A...TD...SA..S.
Q.....	...-A...TA...A..S.
			78
			78
			78
			78
			78

76	E-..EALAGS..T.--S.
77	..-..AE..TSDTAGL-SND
77	..-..AA..TSDTAGL-EKD
77	..-..AA..TSDTAGL-QND
77	..-..AA..TNDADL-QND
77	Q.E-..AA..G-DADL.TAP.
76	Q.E-..PV..T.DTD.A.DI.
75	TIS-..TA..---N.A.DFK
79	T.SG.AAT..QA..N.SNINQ
73	T.S-..A..---S.A.--N

38

E	LT---	ARE	NPAYGRHMQDAEMFTNAACMAINIWDRFDVF	C	TLGASCYL
B	--				T
L1	C---		Y		T
DA	--				T
L2	C---		Y		T
F	SKLVE.T		T		T
L3	P.TNW..P		Y		TT
A	PVANV..P		Y		TT
C	P.TNW..P		Y		TT
H	PKTNV..P		Y		TT

FIG.10C

MoPn	-PA--S..K.....Y.....T.....	139	159
SFPD	TST--P..K.....Y.....T.....		
GPIC	TVA--D.NI.....K.....WS.....FL.....N.....		
Mn	PEAN-G.PI.....E.....W.S.....FL.....N.....F.....		
HuPn	Y.TAVD.PNK.IH.....W.....GFI.....N.....I.....		
VD II				
	KENSASFNLVGLFG	DNENQSTVKTNS-----VPMNSLDQS	174	174
	N...TK..SNGAF-----	175	175
KDA-----F...	174	174
K....AE-----F...	174	174
HA..SDSKL-----	175	175
GV..ATKPAAD..-----I..VQ.N..	175	175
	TKTQSTNFN.AKL-----TA.N.A	177	177
	TKTQS.GFD.ANI-----TA.N.A	177	177
	TKTQS.SFN.AKL-----I..TA.NEA	177	177
	TKTKS.DFN.AKL-----IA.NRA	177	177
A.....	RD.TA-----VAADDI..V..S.A	171	171
GVANAANAIAATVAADSL..V..S.A	180	180
	..A.A.A.....L..	VTG-----TDLQGG---Y..VAIS.G	169	169
	..AS..A.....I..	FSAAS.ISTDLPTQ---L..VGIT.G	178	178
	R...TA.....	VKG--T..N-ANE-----L..V..SNG	170	170

FIG. 10D

	182	184	210	273
E	ARAALWE	C G C	ATLGASFQVAQSKPKVEELNVL	C NAAEFTINKPKGY
B
L1
DA
L2
F	I.....
L3	D.S.....
A	S.....
C	S.....
H	S.....
MoPn
SFPD	Q.....
GPIC	G.....	E.....N.I.M...I	S SPTQ.V.H.R..
Mn	G.....	E.....N.I.M...T	S S P.Q.V.H.R..
HuPn	G.....	E.....	.VSQ.SV.....
			223	233
			VD III	
			VG --QEFPLALIAGTDA	ATGTKDASIDYHEWQA SLASVRLNMF TPTPIG/KWSRA
			--K.L..D.T.....
			--K....D.T.....
			--K....D.T.....
			--...D.K...G V

FIG.10E

..	--K...	D.T...	S.....	274
..	--A...	DIT..E.	V.....	276
..	--A...	DIT..E.	V.....	276
..	--A...	NIT..E.	V.....	276
..	--A...	DIT..E.	V.....	276
..	--	NIK...VS	270
..	--K...	T...S	279
K.	TAAN...	P.T..ES	D..S.T.K...IG...LV...N....	270
K.	ASSN...	PIT...TE	D..S.T.K...VG...LV...N....	280
K.	--VA...	PTD..VAT	S.T.N...VGAS...SLV...Q....	269

287

316

	SFDADTIRIAQPK	SATAIFDITITINPTIAGAG-DVKASA----	EGQLG	DT
E	..ET...V.....	..T.
B	L.....	-E...N.
L1	-...TGT----
DA	..TV..V.....	-----
L2	LV.FW.I.....	C.-S.AGANT----	IS	..
F	..S.....R
L3	L.E.VL.V.....	K.-S.V..GS---NE.A
A	L.KPVL.....	K.-T.VS..----NE.A
C	L.E..L.V.....	K.-S.VSAGT---DNE.A
H	L.E..L.V.....	K.-T.V..GS---DNE.A
MoPn	LE.S.LKM..W....	S.S.I..-----	DIKIT	..

FIG.10F

SFPD	L.E..L.V..W.....	TIADGICAAATANG.A ..
GPIC	T....S.....	LP...INL..W...LL.---	EATTINIG---AKYA .Q
Mn	T.....	LKSE.INI..W..SLI.ST-	TALPNNCK--DV.S .V
HuPn	T....N.....	LP..VINL..AW..SLL.---	NAT.LSTT---DSFS .F

335


MQIVSLQINKMKSRKS	C	GIAVGTTIVDADKYAVTVEIRLIDERAAHVNAQFRE	371
.....	372
.....	371
.....	371
.....	372
.....	373
.....	375
.....	V.....I.....	374
.....A.....	375
.....	375
L.....	L.I.....	365
L.....	L.I.....	382
L..A..I.....A	A.LI...WSI.G.A..N.....	367
L..A.I.I.....A	V..A.LI...WSI.G.A..N....M.....	380
.....C.I..F.....A	VT..A.L.....WSL.A.A..N.....SG....	366

09/647948

Docket No.
T038-1094

Declaration and Power of Attorney For Patent Application

English Language Declaration



As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

DNA IMMUNIZATION AGAINST CHLAMYDIA INFECTION

the specification of which

(check one)

☐ is attached hereto.

☒ was filed on April 7, 1999 as United States Application No. or PCT International

Application Number PCT/CA99/00292

and was amended on July 4, 2000

(if applicable)

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) or Section 365(b) of any foreign application(s) for patent or inventor's certificate, or Section 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate or PCT International application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)

Priority Not Claimed

<u> </u>	<u> </u>	<u> </u>	<input type="checkbox"/>
(Number)	(Country)	(Day/Month/Year Filed)	
<u> </u>	<u> </u>	<u> </u>	<input type="checkbox"/>
(Number)	(Country)	(Day/Month/Year Filed)	
<u> </u>	<u> </u>	<u> </u>	<input type="checkbox"/>
(Number)	(Country)	(Day/Month/Year Filed)	

I hereby claim the benefit under 35 U.S.C. Section 119(e) of any United States provisional application(s) listed below:

(Application Serial No.)

(Filing Date)

(Application Serial No.)

(Filing Date)

(Application Serial No.)

(Filing Date)

I hereby claim the benefit under 35 U. S. C. Section 120 of any United States application(s), or Section 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. Section 112, I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, C. F. R., Section 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application:

09/055,765

April 7, 1998

Pending

(Application Serial No.)

(Filing Date)

(Status)
(patented, pending, abandoned)

PCT/CA99/00292

April 7, 1999

(Application Serial No.)

(Filing Date)

(Status)
(patented, pending, abandoned)

(Application Serial No.)

(Filing Date)

(Status)
(patented, pending, abandoned)

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith. *(list name and registration number)*

Michael I. Stewart (24,973)

Send Correspondence to: Sim & McBurney
6th Floor, 330 University Avenue
Toronto, Ontario
Canada, M5G 1R7.

Direct Telephone Calls to: *(name and telephone number)*
(416) 595-1155

Full name of sole or first inventor Robert C. Brunham	
Sole or first inventor's signature <i>Robert C Brunham</i>	Date <i>Nov. 27, 2020</i>
Residence Vancouver, British Columbia, Canada <i>CA</i>	
Citizenship Canadian	
Post Office Address 2077 655 West 12th Avenue, Vancouver, British Columbia, Canada.	

Full name of second inventor, if any	
Second inventor's signature	Date
Residence	
Citizenship	
Post Office Address	